FDA Brief

Warning letters Drugs

FDA warning letter to

Nose Slap LLC

High riskIssued Apr 24, 2023Posted Apr 25, 2023Center for Drug Evaluation and Research | CDER

FDA told Nose Slap LLC its NOSE SLAP and SOUL SLAP smelling-salt stimulants are unapproved and misbranded drugs.

What happened

FDA reviewed the company's product labels and website, where NOSE SLAP and SOUL SLAP are offered for sale, and concluded from the claims that the products are intended as stimulant drugs. The labels and website describe energy, alertness, focus, and ammonia-induced reflex stimulation; the products contain ammonium chloride, sodium carbonate, and essential oils. FDA said no approved drug application is in effect and the products do not fit the OTC stimulant monograph or the 2008 proposed rule on ammonia reflex stimulants.

What FDA found

  1. FDA says NOSE SLAP and SOUL SLAP are new drugs because they are intended as stimulants and no FDA-approved drug application is in effect for them.

    section 505(a), FD&C Act, 21 U.S.C. 355(a)
  2. FDA says the products are misbranded because they are nonprescription drugs subject to section 505G but do not meet its requirements and lack an approved application.

    section 502(ee), FD&C Act, 21 U.S.C. 352(ee)
  3. FDA treats ammonia-containing smelling salts labeled as reflex stimulants as not generally recognized as safe and effective under its 2008 proposed rule, so the products need an approved application.

    section 505G(a)(4), FD&C Act, 21 U.S.C. 355h(a)(4); 73 FR 34895
  4. Even as general stimulants, the products do not meet OTC Monograph M011 because they contain ammonium chloride and are labeled for intranasal use.

    section 505G, FD&C Act; OTC Monograph M011
  5. FDA says it is not aware of adequate and well-controlled clinical trials showing the products are generally recognized as safe and effective for their labeled uses.

  6. FDA says interstate introduction of the products is prohibited because they are unapproved and misbranded drugs.

    sections 301(a) and 301(d), FD&C Act, 21 U.S.C. 331(a), 331(d)

What FDA wants

FDA asks the company to take prompt action to correct the violations and respond in writing within 15 working days, saying what it has done and how it will prevent recurrence. If it cannot complete corrections in that time, it must give reasons and a completion schedule.

Who should pay attention

  • retailers and online marketplaces selling smelling salts or energy products
  • other OTC stimulant and smelling-salt brands
  • companies using ammonia or reflex-stimulant claims in consumer products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk